Pricing updated 2019-04-24. Prices are subject to change without notice.
The hepatocyte growth factor receptor c-Met commonly shows elevated activity in several forms of cancer.1,2 SGX523 is a potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM.1 It is over 1,000-fold selective for c-Met over a panel of other kinases.1 SGX523 is orally active and dose-dependently inhibits the growth of a variety of tumor xenografts in mice.1,3 The effectiveness of SGX523 is enhanced when combined with other chemotherapeutic compounds, including inhibitors of EGFR.2,4 SGX523 is metabolized, at least in part, by aldehyde oxidase, an enzyme that differs in activity across different species.5
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Buchanan, S.G., Hendle, J., Lee, P.S., et al. SGX523 is an exquisitely selective, ATP-
Padda, S., Neal, J.W., and Wakelee, H.A. MET inhibitors in combination with other therapies in non-
Guessous, F., Zhang, Y., diPierro, C., et al. An orally bioavailable c-
Zhang, Y.W., Staal, B., Essenburg, C., et al. Strengthening context-
Diamond, S., Boer, J., Maduskuie, T.P., Jr., et al. Species-